Actively Recruiting

Phase 1
Age: 18Years - 70Years
All Genders
NCT05836948

The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors

Led by Shanghai Hengrui Pharmaceutical Co., Ltd. · Updated on 2025-08-11

174

Participants Needed

1

Research Sites

158 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study is an open-label, phase I clinical trial of SHR-9839 in patients with advanced solid tumors. The whole study is divided into three stages: dose escalation, dose expansion and efficacy expansion.

CONDITIONS

Official Title

The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors

Who Can Participate

Age: 18Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with confirmed unresectable locally advanced or metastatic solid tumors relapsed or refractory to standard treatment, or without applicable standard treatment
  • At least one measurable tumor lesion per RECIST v1.1
  • ECOG performance status of 0 or 1
  • Life expectancy of 12 weeks or more
  • Adequate bone marrow and organ function
  • Voluntary agreement to participate and signed informed consent
Not Eligible

You will not qualify if you...

  • Active central nervous system or meningeal metastases
  • Anti-tumor treatment (chemotherapy, biotherapy, targeted therapy, immunotherapy, radical radiotherapy, or other clinical research treatments) within 4 weeks before first dose
  • History of serious cardiovascular or cerebrovascular diseases
  • Radiation therapy over 30Gy within 4 weeks before first dose, or 30Gy or less of palliative radiation within 7 days before first dose
  • Previous anti-tumor treatment adverse reactions not recovered to Grade 1 or less per NCI-CTCAE v5.0

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Zhejiang Tumor Hospital

Hangzhou, Zhejiang, China, 310006

Actively Recruiting

Loading map...

Research Team

R

Rongfu Mao, MD

CONTACT

J

Jin Wang, COD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here